107 related articles for article (PubMed ID: 7513980)
21. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
22. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
23. Hairy-cell leukemia and alpha-interferon treatment: long-term responders.
Zinzani PL; Lauria F; Salvucci M; Rondelli D; Raspadori D; Bendandi M; Magagnoli M; Tura S
Haematologica; 1997; 82(2):152-5. PubMed ID: 9175317
[TBL] [Abstract][Full Text] [Related]
24. A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia.
Meloni G; Russo D; Baccarani M; Testoni N; Martinelli G; Fanin R; Zuffa E; Rosti G; Alimena G; Saglio G; Mandelli F; Tura S
Haematologica; 1999 Aug; 84(8):707-15. PubMed ID: 10457406
[TBL] [Abstract][Full Text] [Related]
25. [Molecular biology follow-up of interferon therapy in patients with chronic myeloid leukemia].
Iványi JL; Marton E; Kereskai L; Kiss Z; Pajor L
Orv Hetil; 2000 Nov; 141(47):2527-33. PubMed ID: 11143285
[TBL] [Abstract][Full Text] [Related]
26. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
[TBL] [Abstract][Full Text] [Related]
27. High response rate using recombinant interferon-alpha in patients with newly diagnosed chronic myeloid leukemia.
Mahon FX; Fabères C; Montastruc M; Si-Mour S; Boiron JM; Marit G; Bilhou-Nabera C; Cony-Makhoul P; Pigneux A; Bernard P; Broustet A; Reiffers J
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S33-7. PubMed ID: 8769698
[TBL] [Abstract][Full Text] [Related]
28. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Cortes J; O'Brien S; Faderl S; Thomas D; Giles F; Rios MB; Shan J; Arlinghaus R
Clin Cancer Res; 2003 Jan; 9(1):160-6. PubMed ID: 12538464
[TBL] [Abstract][Full Text] [Related]
29. [Interferon alpha--the drug of choice for patients with chronic myeloid leukemia].
Klamová H; Vítek A; Michalová K; Brezinová J; Moravcová J; Jelínek J; Cermák J
Cas Lek Cesk; 1998 Sep; 137(18):552-6. PubMed ID: 9818464
[TBL] [Abstract][Full Text] [Related]
30. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
31. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
32. [Interferon therapy in hematologic neoplasms].
Schwarzinger I; Bettelheim P; Lechner K
Wien Klin Wochenschr; 1988 Aug; 100(15):497-504. PubMed ID: 2459854
[TBL] [Abstract][Full Text] [Related]
33. The role of interferons in the treatment of hematologic malignancies.
Gutterman JU
Semin Hematol; 1988 Jul; 25(3 Suppl 3):3-8. PubMed ID: 2459780
[TBL] [Abstract][Full Text] [Related]
34. Sequential treatment of hairy cell leukemia: a new role for interferon.
Golomb HM; Ratain MJ; Vardiman JW
Important Adv Oncol; 1986; ():311-21. PubMed ID: 2454218
[TBL] [Abstract][Full Text] [Related]
35. [Interferons in hemato-cancerology].
Boiron M
Nouv Rev Fr Hematol (1978); 1987; 29(1):49-55. PubMed ID: 2438645
[TBL] [Abstract][Full Text] [Related]
36. [Interferons and hematology].
Lacotte-Thierry L; Guilhot F
Rev Med Interne; 2002 Nov; 23 Suppl 4():481s-488s. PubMed ID: 12481403
[TBL] [Abstract][Full Text] [Related]
37. [Various aspects and results of therapy with interferon].
Niederle N
Arzneimittelforschung; 1988 Mar; 38(3A):449-53. PubMed ID: 2456071
[TBL] [Abstract][Full Text] [Related]
38. Biotherapy with interferon--1988.
Figlin RA
Semin Oncol; 1988 Dec; 15(6 Suppl 6):3-9. PubMed ID: 2462749
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of leukemias and lymphomas with interferons: I. Trial of myeloma therapy with human beta-interferon].
Misset JL; Mathé G; Gastiaburu J; Goutner A; Dorval T; Gouveia J; Hayat M; Jasmin C; Schwarzenburg L; Machover D; Ribaud P; De Vassal F; Horosezewicz JS
Biomed Pharmacother; 1982 Jan; 36(1):55-9. PubMed ID: 6181822
[TBL] [Abstract][Full Text] [Related]
40. [Quantitative-kinetic aspects of granulocytic resistance to infection in hematologic systemic diseases with reference to antineoplastic chemotherapy].
Sommer S
Z Arztl Fortbild (Jena); 1988; 82(11):513-5. PubMed ID: 3176536
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
